Explore 3 Stock Ideas & Industry Insights Download Free Report

News

CXApp Inc. (NASDAQ: CXAI) Reports 2024 Financial Results and AI-Centric Transformation

CXApp Inc. (NASDAQ: CXAI) has announced positive financial results for 2024, marking a successful transition to an AI-focused subscription application business. The company’s strategy of shifting to AI-driven products has resulted in notable improvements in its financial performance, customer retention, and operational efficiency.

Team Kalkine | 04 April 2025

Gold Resource (NYSE American: GORO) Reports Positive Exploration Results at Don David Gold Mine

Gold Resource (NYSE American: GORO) has announced positive results from its 2024 exploration drilling program at the Don David Gold Mine in Oaxaca, Mexico. The exploration focused on the Three Sisters and Gloria vein systems, revealing significant mineral discoveries. A total of 23 underground …

Team Kalkine | 04 April 2025

Lianhe Sowell International Group (NASDAQ: LHSW) Debuts on Nasdaq, Raises $8 Million

Lianhe Sowell International Group (NASDAQ: LHSW) made its Nasdaq debut on April 3, 2025, raising $8 million in gross proceeds. The company specializes in machine vision solutions, incorporating advanced technologies such as image processing, sound imaging, and video analysis. Lianhe Sowell's key innovations include …

Team Kalkine | 04 April 2025

Mesoblast (Nasdaq: MESO) Announces Exemption from U.S. Tariffs for Allogeneic Cellular Products

Mesoblast (Nasdaq: MESO) has confirmed that its allogeneic cellular products, including Ryoncil® and Revascor®, will be exempt from U.S. tariffs. This exemption is made possible because the company’s products are designated as “U.S. Country of Origin” products. All products are manufactured using U.S. donors …

Team Kalkine | 04 April 2025

Telix Pharmaceuticals (ASX/NASDAQ: TLX) Appoints Anne Whitaker as Non-Executive Director

Telix Pharmaceuticals (ASX/NASDAQ: TLX) has appointed Anne Whitaker as a Non-Executive Director, effective April 7, 2025. Whitaker's appointment brings a wealth of knowledge and experience to the company, stemming from over three decades in the pharmaceutical, biotech, and specialty pharmaceutical sectors.

Team Kalkine | 04 April 2025

FDA Grants Accelerated Approval for Novartis' Vanrafia® in IgA Nephropathy

Phase III ALIGN Study:Approval is based on interim data from a clinical trial showing proteinuria reduction at 36 weeks. Full results, including kidney function impact, are expected in 2026.

Team Kalkine | 03 April 2025

PVH Exceeds Q4 Earnings Estimates Despite Revenue Decline, Plans $500M Share Buyback

Revenue Decline:Sales fell 5% to $2.372 billion, but still topped forecasts of $2.33 billion.

Team Kalkine | 03 April 2025

Johnson & Johnson Stock Plunges as Judge Rejects $10B Talc Settlement Plan

Stock Drops:J&J shares fell 7.6%, closing at $153.25, marking a sharp reversal from its recent breakout.

Team Kalkine | 03 April 2025